The Journal of Urology · 2008 · 61 citations · 17 references
MedicineOncologyUrologyMetastasisMolecular OncologyTumor ProgressionBiomarkers In Urologic OncologyCancer BiomarkersKidney CancerMetastatic Urologic CancerRenal Cell CarcinomaRenal NeoplasmsBiomarkers For Metastatic DiseaseCytoreductive NephrectomyMetastatic Kidney CancerRenal Cell Carcinoma BiomarkersRenal MalignancyTumor Suppressor LossVon Hippel-lindau DiseaseVon Hippel-lindau Syndrome
PURPOSE: We explored the prognostic impact of C-reactive protein status in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. MATERIALS AND METHODS: The oncological outcome of 40 patients with metastatic renal cell carcinoma (TxpN1M0, TxNxM1) who underwent cytoreductive nephrectomy was analyzed. The C-reactive protein level was measured before and 1 month after cytoreductive nephrectomy. The normal value of C-reactive protein was considered less than 0.5 mg/dl. RESULTS: During the median followup of 14 months 31 patients (78%) died of the disease. The preoperative C-reactive protein level was not increased in 17 of the 40 patients (nonelevated group). Of the remaining 23 patients with a preoperatively increased C-reactive protein level, after cytoreductive nephrectomy the C-reactive protein level normalized in 17 (normalized group). However, in the remaining 6 patients the C-reactive protein level did not normalize and remained high during followup (nonnormalized group). All of the patients in nonnormalized group died of the disease within 1 year. The overall survival rate of the nonnormalized group was significantly worse than that of the other 2 groups (p <0.0001). No significant difference was found in terms of overall survival rate between the normalized and nonelevated groups (p = 0.22). Multivariate analysis demonstrated that nonnormalized C-reactive protein (p <0.0001), absence of metastatectomy (p = 0.005), poorer performance status (p = 0.006) and bone metastases (p = 0.023) were independent factors for predicting poorer overall survival. CONCLUSIONS: The current study indicated that C-reactive protein kinetics would predict the clinical course of patients with metastatic renal cell carcinoma who underwent cytoreductive nephrectomy. Larger confirmatory studies would be warranted to validate the current results.
17
Interleukin‐6 (IL‐6) functions as an in vitro autocrine growth factor in renal cell carcinomas
Shunji Miki, Masayuki Iwano, Yoshitsugu Miki et al. · FEBS Letters · 1989 · 416 citations
Medicine, Cancer Biology, Oncology +14
Evaluation of an inflammation‐based prognostic score in patients with metastatic renal cancer
Sara Ramsey, Gavin W.A. Lamb, Michael Aitchison et al. · Cancer · 2006 · 334 citations · Full text
Medicine, Oncology, Breast Oncology +14
Metastatic renal carcinoma comprehensive prognostic system
Jens Atzpodien, Patrick Royston, T Wandert et al. · British Journal of Cancer · 2003 · 242 citations · Full text
Medicine, Oncology, Pharmacology +17